Novel anti-mfi2 antibodies and methods of use
US-2017320960-A1 · Nov 9, 2017 · US
Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer
US12134650B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12134650-B2 |
| Application number | US-201917263251-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 25, 2019 |
| Priority date | Jul 26, 2018 |
| Publication date | Nov 5, 2024 |
| Grant date | Nov 5, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods of treating cancer are provided. Accordingly, there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent capable of (i) specifically binding GABRA2, the agent comprising a therapeutic moiety; and/or (ii) downregulating activity and/or expression of said GABRA2. Also provided are compositions, article of manufactures and methods of diagnosing cancer and monitoring cancer treatment.
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody comprising an antigen recognition domain which specifically binds GABRA2 and comprises complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 18, 19 and 20 arranged in a sequential order from N to C on a light chain of the antibody and CDRs as set forth in SEQ ID NOs: 8, 9 and 10 arranged in a sequential order from N to C on a heavy chain of said antibody. 2. The antibody of claim 1 comprising a heterologous therapeutic moiety. 3. A method of treating neuroblastoma in a subject in need thereof, the method comprising administering to the subject an effective amount of an antibody comprising an antigen recognition domain which specifically binds GABRA2 and comprises complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 18, 19 and 20 arranged in a sequential order from N to C on a light chain of the antibody and CDRs as set forth in SEQ ID NOs: 8, 9 and 10 arranged in a sequential order from N to C on a heavy chain of said antibody, thereby treating the neuroblastoma.
Assignees
Inventors
Classifications
involving compounds localised on the membrane of tumour or cancer cells · CPC title
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title
for neuromediators, e.g. serotonin receptor, dopamine receptor · CPC title
Expression markers · CPC title
for cancer (immunoassay for cancer G01N33/575) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12134650B2 cover?
- Methods of treating cancer are provided. Accordingly, there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent capable of (i) specifically binding GABRA2, the agent comprising a therapeutic moiety; and/or (ii) downregulating activity and/or expression of said GABRA2. Also provided are compositi…
- Who is the assignee on this patent?
- Tel Hashomer Medical Res Infrastructure & Services Ltd, Tageza Biopharmaceuticals Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/286. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).